M&T Bank Corp increased its stake in shares of AxoGen, Inc (NASDAQ:AXGN) by 21.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 16,123 shares
AxoGen, Inc (NASDAQ:AXGN) – Analysts at Jefferies Financial Group lowered their Q2 2020 earnings per share (EPS) estimates for shares of AxoGen in a note issued to investors on Tuesday, February 25t
AxoGen, Inc (NASDAQ:AXGN) – Equities researchers at Svb Leerink issued their Q1 2020 earnings per share estimates for shares of AxoGen in a research note issued to investors on Tuesday, February 25t
It's been a sad week for AxoGen, Inc. (NASDAQ:AXGN), who've watched their investment drop 13% to US$12.99 in the week...
Puraply is a key growth driver of Organogenesis’ advanced wound care business. There are multiple short-term, mid-term, and long-term growth catalysts for the c

95 Biggest Movers From Yesterday

12:00am, Thursday, 27'th Feb 2020
It's been a mediocre week for AxoGen, Inc. (NASDAQ:AXGN) shareholders, with the stock dropping 18% to US$12.12 in the...

80 Biggest Movers From Yesterday

10:32am, Wednesday, 26'th Feb 2020
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 77.4% to close at $5.80 on Tuesday. Cocrystal Pharma Inc (NASDAQ: COCP) shares surged 64.7% to close at $2.19 on...
Shares of AxoGen, Inc (NASDAQ:AXGN) were down 17% on Tuesday following a dissappointing earnings announcement. The stock traded as low as $11.80 and last traded at $12.12, approximately 926,569 shares

AxoGen (AXGN) Receives a Buy from BTIG

02:32pm, Tuesday, 25'th Feb 2020
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on AxoGen (AXGN), with a price target of $19.00. The company's shares

AxoGen (AXGN) Receives a Buy from BTIG

02:32pm, Tuesday, 25'th Feb 2020
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on AxoGen (AXGN – Research Report), with
AxoGen (NASDAQ:AXGN) released its quarterly earnings data on Monday. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09)
AxoGen (NASDAQ:AXGN)‘s stock had its “buy” rating reiterated by research analysts at Canaccord Genuity in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE